| 1. |
|
|
| 2. |
- Gray, Marcus A, et al.
(författare)
-
Modulation of emotional appraisal by false physiological feedback during fMRI.
- 2007
-
Ingår i: PLoS ONE. - 1932-6203. ; 2:6, s. e546-
-
Tidskriftsartikel (refereegranskat)abstract
- James and Lange proposed that emotions are the perception of physiological reactions. Two-level theories ofemotion extend this model to suggest that cognitive interpretations of physiological changes shape self-reported emotions.Correspondingly false physiological feedback of evoked or tonic bodily responses can alter emotional attributions. Moreover,anxiety states are proposed to arise from detection of mismatch between actual and anticipated states of physiologicalarousal. However, the neural underpinnings of these phenomena previously have not been examined. Methodology/Principal Findings. We undertook a functional brain imaging (fMRI) experiment to investigate how both primary and secondorderlevels of physiological (viscerosensory) representation impact on the processing of external emotional cues. 12participants were scanned while judging face stimuli during both exercise and non-exercise conditions in the context of trueand false auditory feedback of tonic heart rate. We observed that the perceived emotional intensity/salience of neutral faceswas enhanced by false feedback of increased heart rate. Regional changes in neural activity corresponding to this behaviouralinteraction were observed within included right anterior insula, bilateral mid insula, and amygdala. In addition, right anteriorinsula activity was enhanced during by asynchronous relative to synchronous cardiac feedback even with no change inperceived or actual heart rate suggesting this region serves as a comparator to detect physiological mismatches. Finally, BOLDactivity within right anterior insula and amygdala predicted the corresponding changes in perceived intensity ratings at botha group and an individual level. Conclusions/Significance. Our findings identify the neural substrates supportingbehavioural effects of false physiological feedback, and highlight mechanisms that underlie subjective anxiety states,including the importance of the right anterior insula in guiding second-order ‘‘cognitive’’ representations of bodily arousalstate.
|
|
| 3. |
- Hejnol, A, et al.
(författare)
-
Assessing the root of bilaterian animals with scalable phylogenomic methods
- 2009
-
Ingår i: Proceedings of the Royal Society B. ; 276:1677, s. 4261-4270
-
Tidskriftsartikel (refereegranskat)abstract
- A clear picture of animal relationships is a prerequisite to understand how the morphological and ecological diversity of animals evolved over time. Among others, the placement of the acoelomorph flatworms, Acoela and Nemertodermatida, has fundamental implications for the origin and evolution of various animal organ systems. Their position, however, has been inconsistent in phylogenetic studies using one or several genes. Furthermore, Acoela has been among the least stable taxa in recent animal phylogenomic analyses, which simultaneously examine many genes from many species, while Nemertodermatida has not been sampled in any phylogenomic study. New sequence data are presented here from organisms targeted for their instability or lack of representation in prior analyses, and are analysed in combination with other publicly available data. We also designed new automated explicit methods for identifying and selecting common genes across different species, and developed highly optimized supercomputing tools to reconstruct relationships from gene sequences. The results of the work corroborate several recently established findings about animal relationships and provide new support for the placement of other groups. These new data and methods strongly uphold previous suggestions that Acoelomorpha is sister clade to all other bilaterian animals, find diminishing evidence for the placement of the enigmatic Xenoturbella within Deuterostomia, and place Cycliophora with Entoprocta and Ectoprocta. The work highlights the implications that these arrangements have for metazoan evolution and permits a clearer picture of ancestral morphologies and life histories in the deep past.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
- Weber, Michael A, et al.
(författare)
-
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension : a randomised, double-blind, placebo-controlled trial
- 2009
-
Ingår i: The Lancet. - : Elsevier. - 0140-6736 .- 1474-547X. ; 374:9699, s. 1423-1431
-
Tidskriftsartikel (refereegranskat)abstract
- BackgroundHypertension cannot always be adequately controlled with available drugs. We investigated the blood-pressure-lowering effects of the new vasodilatory, selective endothelin type A antagonist, darusentan, in patients with treatment-resistant hypertension.MethodsThis randomised, double-blind study was undertaken in 117 sites in North and South America, Europe, New Zealand, and Australia. 379 patients with systolic blood pressure of 140 mm Hg or more (≥130 mm Hg if patient had diabetes or chronic kidney disease) who were receiving at least three blood-pressure-lowering drugs, including a diuretic, at full or maximum tolerated doses were randomly assigned to 14 weeks' treatment with placebo (n=132) or darusentan 50 mg (n=81), 100 mg (n=81), or 300 mg (n=85) taken once daily. Randomisation was made centrally via an automated telephone system, and patients and all investigators were masked to treatment assignments. The primary endpoints were changes in sitting systolic and diastolic blood pressures. Analysis was by intention to treat. The study is registered with ClinicalTrials.gov, number NCT00330369.FindingsAll randomly assigned participants were analysed. The mean reductions in clinic systolic and diastolic blood pressures were 9/5 mm Hg (SD 14/8) with placebo, 17/10 mm Hg (15/9) with darusentan 50 mg, 18/10 mm Hg (16/9) with darusentan 100 mg, and 18/11 mm Hg (18/10) with darusentan 300 mg (p<0·0001 for all effects). The main adverse effects were related to fluid accumulation. Oedema or fluid retention occurred in 67 (27%) patients given darusentan compared with 19 (14%) given placebo. One patient in the placebo group died (sudden cardiac death), and five patients in the three darusentan dose groups combined had cardiac-related serious adverse events.InterpretationDarusentan provides additional reduction in blood pressure in patients who have not attained their treatment goals with three or more antihypertensive drugs. As with other vasodilatory drugs, fluid management with effective diuretic therapy might be needed.
|
|
